GB0202282D0 - Treatment of male sexual dysfunction - Google Patents

Treatment of male sexual dysfunction

Info

Publication number
GB0202282D0
GB0202282D0 GBGB0202282.0A GB0202282A GB0202282D0 GB 0202282 D0 GB0202282 D0 GB 0202282D0 GB 0202282 A GB0202282 A GB 0202282A GB 0202282 D0 GB0202282 D0 GB 0202282D0
Authority
GB
United Kingdom
Prior art keywords
treatment
sexual dysfunction
male sexual
male
dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0202282.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Priority to GBGB0202282.0A priority Critical patent/GB0202282D0/en
Publication of GB0202282D0 publication Critical patent/GB0202282D0/en
Priority to AU2003201471A priority patent/AU2003201471B2/en
Priority to KR1020047011672A priority patent/KR100829262B1/ko
Priority to CNB038030535A priority patent/CN100500658C/zh
Priority to KR1020077029747A priority patent/KR20080011232A/ko
Priority to JP2003564025A priority patent/JP2005525321A/ja
Priority to BR0307337-8A priority patent/BR0307337A/pt
Priority to EP03700164A priority patent/EP1470115A1/en
Priority to NZ546408A priority patent/NZ546408A/en
Priority to CA002474590A priority patent/CA2474590A1/en
Priority to PCT/IB2003/000140 priority patent/WO2003064402A1/en
Priority to IL16282203A priority patent/IL162822A0/xx
Priority to MXPA04007434A priority patent/MXPA04007434A/es
Priority to PL03371415A priority patent/PL371415A1/xx
Priority to US10/350,924 priority patent/US20030229001A1/en
Priority to TW092101731A priority patent/TW200302732A/zh
Priority to ZA2004/05208A priority patent/ZA200405208B/en
Priority to IL162822A priority patent/IL162822A/en
Priority to HK05105801.3A priority patent/HK1073109A1/xx
Priority to US12/339,549 priority patent/US20090175793A1/en
Priority to JP2010079241A priority patent/JP2010209075A/ja
Priority to US12/987,345 priority patent/US20110107442A1/en
Priority to US13/742,613 priority patent/US20130121923A1/en
Priority to JP2013038357A priority patent/JP2013151511A/ja
Priority to US14/495,537 priority patent/US20150072995A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
GBGB0202282.0A 2002-01-31 2002-01-31 Treatment of male sexual dysfunction Ceased GB0202282D0 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GBGB0202282.0A GB0202282D0 (en) 2002-01-31 2002-01-31 Treatment of male sexual dysfunction
NZ546408A NZ546408A (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction
MXPA04007434A MXPA04007434A (es) 2002-01-31 2003-01-20 Tratamiento de la disfuncion sexual masculina.
PL03371415A PL371415A1 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction
CNB038030535A CN100500658C (zh) 2002-01-31 2003-01-20 用于男性性功能障碍的治疗的药物组合物
KR1020077029747A KR20080011232A (ko) 2002-01-31 2003-01-20 수컷의 성 기능 부전을 치료하는 방법
JP2003564025A JP2005525321A (ja) 2002-01-31 2003-01-20 雄性の性機能障害の治療
BR0307337-8A BR0307337A (pt) 2002-01-31 2003-01-20 Tratamento de disfunção sexual masculina
EP03700164A EP1470115A1 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction
KR1020047011672A KR100829262B1 (ko) 2002-01-31 2003-01-20 수컷의 성 기능 부전을 치료하는 방법
CA002474590A CA2474590A1 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction
PCT/IB2003/000140 WO2003064402A1 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction
IL16282203A IL162822A0 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction
AU2003201471A AU2003201471B2 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction
US10/350,924 US20030229001A1 (en) 2002-01-31 2003-01-24 Treatment of male sexual dysfunction
TW092101731A TW200302732A (en) 2002-01-31 2003-01-27 Treatment of male sexual dysfunction
ZA2004/05208A ZA200405208B (en) 2002-01-31 2004-06-30 Treatment of male sexual dysfunction
IL162822A IL162822A (en) 2002-01-31 2004-07-01 Use of a selective oxytocin receptor antagonist in the manufacture of medicaments for the treatment of premature ejaculation, an assay method for identifying such agonists and pharmaceutical compositions consisting of one or more of said antagonists and one or more pdeis
HK05105801.3A HK1073109A1 (en) 2002-01-31 2005-07-11 Pharmaceutical composition for treatment of male sexual dysfunction
US12/339,549 US20090175793A1 (en) 2002-01-31 2008-12-19 Treatment of male sexual dysfunction
JP2010079241A JP2010209075A (ja) 2002-01-31 2010-03-30 雄性の性機能障害の治療
US12/987,345 US20110107442A1 (en) 2002-01-31 2011-01-10 Treatment of Male Sexual Dysfunction
US13/742,613 US20130121923A1 (en) 2002-01-31 2013-01-16 Treatment of Male Sexual Dysfunction
JP2013038357A JP2013151511A (ja) 2002-01-31 2013-02-28 雄性の性機能障害の治療
US14/495,537 US20150072995A1 (en) 2002-01-31 2014-09-24 Treatment of male sexual dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202282.0A GB0202282D0 (en) 2002-01-31 2002-01-31 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
GB0202282D0 true GB0202282D0 (en) 2002-03-20

Family

ID=9930155

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0202282.0A Ceased GB0202282D0 (en) 2002-01-31 2002-01-31 Treatment of male sexual dysfunction

Country Status (16)

Country Link
EP (1) EP1470115A1 (pt)
JP (3) JP2005525321A (pt)
KR (2) KR100829262B1 (pt)
CN (1) CN100500658C (pt)
AU (1) AU2003201471B2 (pt)
BR (1) BR0307337A (pt)
CA (1) CA2474590A1 (pt)
GB (1) GB0202282D0 (pt)
HK (1) HK1073109A1 (pt)
IL (2) IL162822A0 (pt)
MX (1) MXPA04007434A (pt)
NZ (1) NZ546408A (pt)
PL (1) PL371415A1 (pt)
TW (1) TW200302732A (pt)
WO (1) WO2003064402A1 (pt)
ZA (1) ZA200405208B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
EP0679084A1 (en) * 1992-12-23 1995-11-02 Merck & Co. Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
US5693805A (en) * 1993-03-12 1997-12-02 Merck & Co., Inc. Process to derivatives of piperizinylcamphorsulfonyl oxytocin antagonists
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
US20020028799A1 (en) * 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
ZA200405208B (en) 2005-08-31
JP2010209075A (ja) 2010-09-24
NZ546408A (en) 2007-10-26
JP2005525321A (ja) 2005-08-25
CN1625553A (zh) 2005-06-08
CA2474590A1 (en) 2003-08-07
KR100829262B1 (ko) 2008-05-13
IL162822A0 (en) 2005-11-20
BR0307337A (pt) 2004-12-07
WO2003064402A1 (en) 2003-08-07
PL371415A1 (en) 2005-06-13
MXPA04007434A (es) 2004-10-11
KR20080011232A (ko) 2008-01-31
CN100500658C (zh) 2009-06-17
KR20040079958A (ko) 2004-09-16
AU2003201471B2 (en) 2009-03-26
EP1470115A1 (en) 2004-10-27
TW200302732A (en) 2003-08-16
JP2013151511A (ja) 2013-08-08
HK1073109A1 (en) 2005-09-23
IL162822A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
PL377729A1 (pl) Sposób leczenia dysfunkcji seksualnej
IL153492A0 (en) Treatment of male sexual dysfunction
AU2003248888A8 (en) Peptide composition for treatment of sexual dysfunction
HK1040901A1 (en) Treatment of female sexual dysfunction
GB0225908D0 (en) Treatment of female sexual dysfunction
ZA200410009B (en) Compositions and methods for ameliorating of human female sexual dysfunction
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
AU2002238106A1 (en) Melanocortin metallopeptides for treatment of sexual dysfunction
GB2408558B (en) Treatment of pipes
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
EP1648430A4 (en) TREATMENT FOR EJACULATIO PRAECOX
GB2386555B (en) Treatment of female sexual dysfunction
IL166273A0 (en) Methods of treatment of male erectile dysfunction
IL162455A0 (en) Compounds for the treatment of sexual dysfunction
IL155775A0 (en) Treatment of male sexual dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
AU2003260818A8 (en) Treatment of immune system dysfunction
AP2004003174A0 (en) Treatment of water
GB0202282D0 (en) Treatment of male sexual dysfunction
GB0108730D0 (en) Treatment of male sexual dysfunction
GB0106167D0 (en) Treatment of male sexual dysfunction
GB0108483D0 (en) Treatment of male sexual dysfunction
GB0120679D0 (en) Treatment of male sexual dysfunction
GB0316673D0 (en) Treatment of female sexual dysfunction
GB0221712D0 (en) Methods of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)